Eligible Drug Costs Need Defining In Medicare Clinical Trial Policy, GSK Says: Drug Firms Recommend Revisions
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I studies and public access to data generated by CMS-approved research under national coverage determinations.